지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, through surgical or medical castration, is the cornerstone of first-line therapy for hormone-naïve metastatic prostate cancer. Recently reported results of clinical trials have given answers to questions regarding the best therapeutic agents and strategies, and these have broadened the scope of evidence-based therapy in this field. Although hormone therapy is very effective, the majority of patients eventually develop resistance to hormonal manipulation, leading to so-called castration-resistant prostate cancer. For castration-resistant prostate cancer, docetaxel-based chemotherapy had been the only approved agent to show a survival benefit for several years. However, over the last five years, significant advances in the field have led to the approval of several new agents with different mechanisms of action, such as the new androgen pathway inhibitors abiraterone and enzalutamide, a new cytotoxic agent, cabazitaxel, and new bone-seeking agents such as radium-223, which have all been associated with improved quality of life and pain palliation and an increase in survival.
Herein, recent developments in hormone therapy and chemotherapy for advanced prostate cancer are reviewed and some of the trials with important results are summarized. As treatment options have expanded and developed rapidly, the selection of the most appropriate agent and administration method through multidisciplinary management is much more important than simply giving newly approved agents to maximize the clinical outcome for patients with advanced, especially castration-resistant, prostate cancer.
목차
등록된 정보가 없습니다.
참고문헌 (45)
참고문헌 신청
Sharifi N / 2005 / Androgen deprivation therapy for prostate cancer / JAMA 294:238~244
Seidenfeld J / 2000 / Single-therapy androgen suppression in men with advanced prostate cancer : a systematic review and meta-analysis / Ann Intern Med 132:566~577
Shore ND / 2011 / Prostate-specific antigen (PSA) progression-free survival (PFS): a comparison of degarelix versus leuprolide in patients with prostate cancer / J Clin Oncol 29(7)
Anderson J. / 2003 / The role of antiandrogen monotherapy in the treat-ment of prostate cancer / BJU Int 91:455~461
Tyrrell CJ / 1998 / A randomised comparison of 'Casodexʼ(bicalutamide)150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer / Eur Urol 33:447~456
Seidenfeld J / 2000 / Single-therapy androgen suppression in men with advanced prostate cancer : a systematic review and meta-analysis / Ann Intern Med 132:566~577
Shore ND / 2011 / Prostate-specific antigen (PSA) progression-free survival (PFS): a comparison of degarelix versus leuprolide in patients with prostate cancer / J Clin Oncol 29(7)
Anderson J. / 2003 / The role of antiandrogen monotherapy in the treat-ment of prostate cancer / BJU Int 91:455~461
Tyrrell CJ / 1998 / A randomised comparison of 'Casodexʼ(bicalutamide)150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer / Eur Urol 33:447~456
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
한국임상암학회 전이성 전립선암 치료 지침
대한내과학회지
2017 .01
-
Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Multimodality Treatment for Patients with Node-Positive Prostate Cancer: the Role of Radiation Therapy
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
Yonsei Medical Journal
2023 .02
-
전립선암 치료의 한방 임상 진료 지침
대한암한의학회지
2016 .01
-
Epidemiology of Prostate Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
전립선암의 영상의학적 소견
대한의사협회지
2015 .01
-
전이성 유방암의 호르몬 치료
대한내과학회지
2017 .06
-
How Precisely Can Prostate Cancer Be Managed?
International Neurourology Journal
2016 .01
-
Prostate cancer screening
Investigative and Clinical Urology
2017 .01
-
The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population
Investigative and Clinical Urology
2019 .01
-
Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Animal models of bone metastatic prostate cancer
Investigative and Clinical Urology
2023 .05
-
Enhancing Knowledge, Beliefs, and Intention to Screen for Prostate Cancer via Different Health Educational Interventions: a Literature Review
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Sleep Disturbance in Patients with Prostate Cancer: A scoping review
성인간호학회 학술대회
2021 .08
-
전립선암 환자의 수면장애: 주제범위 문헌고찰
성인간호학회지
2022 .02
-
The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
International Neurourology Journal
2016 .12
-
Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
Investigative and Clinical Urology
2022 .03
-
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer
Investigative and Clinical Urology
2020 .01
-
The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer
Investigative and Clinical Urology
2017 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0